DNMT3B and hepatocellular carcinoma: Targeting DNMT3b enhances sorafenib sensitivity and improves its therapeutic efficacy against sorafenib-resistant HCC cells, particularly in HBV+ HCC [111] findings demonstrate that epigenetic drug resistance mechanisms and therapeutic strategies in HCC exhibit significant heterogeneity depending on etiological drivers.